Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
NAD+
Batch #
N/A
Formula
C21H27N7O14P2
Mol Wt
663.43 g/mol
CAS
53-84-9
Latest
ISO 17025
8× Testing
99.63%
Purity
VariantNAD+
COA ##13123
Labeled1000mg
Validation KeyAXISBIOTECH
Tested05/12/26
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.63%
✓
Net Peptide Content - 1000mg
✓
Identity (HPLC) - NAD+
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >99%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity
02
Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging
03
NAD+ repletion improves muscle function in muscular dystrophy and counters global parkinsonism in old mice
04
NAD+ metabolism and its roles in cellular processes during ageing
05
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
